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Abstract 
Objective: To investigate the expression of glioma-associated oncogene homolog 1(Gli-1) in 
colon cancer and its association with clinicopathological parameters and postoperative liver 
metastasis.  
Methods: Expression of Gli-1 was detected by immunohistochemistry in paraffin-embedded 
specimens of 96 cases of colon cancer. Relationship between Gli-1 expression and clinico-
pathological parameters, postoperative liver metastasis were analyzed.  
Results: Gli-1 protein expression was significantly increased in colon cancer tissues com-
pared to normal colon tissues (P = 0.037). Gli-1 expression in colon tissues was increased in 
patients with lymph node metastases (P = 0.022) and higher T stages (P = 0.030). Postoper-
ative live metastasis-free survival period was significantly longer in low Gli-1 expression group 
than  that  of  high  Gli-1  expression  group  (48.22±10.03  months  vs  20.46±6.32  months, 
P=0.001). Multivariate analysis showed that Gli-1 expression level is an independent prog-
nostic factor for postoperative live metastasis-free survival. 
Conclusion: Colon cancer is associated with an upregulation of Gli-1 protein expression in 
colon tissues. In patients with colon cancer, Gli-1 expression level is closely related to lymph 
node metastases, T stages and postoperative live metastasis-free survival periods, indicative of 
a possible role of Gli-1 expression in colon cancer progression. 
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Introduction 
Colon cancer is one of the most common human 
malignancies  and  a  major  cause  of  cancer  related 
death worldwide [1]. The major cause of death from 
colon cancer is liver metastasis, which is usually re-
sistant to conventional therapies [2]. 35%-55% of pa-
tients with colon cancer will develop liver metastases 
during  the  course  of  illness.  Survival  following  he-
patic  resection  of  colorectal  metastasis  now  ap-
proaches 35%-50%. However, the recurrence rate in 5 
years is as high as approximately 65% [3]. To date, the 
precise mechanisms leading to liver metastasis in co-
lon cancer remains unknown, and biomarkers for liv-
er metastasis are still lacking. 
The hedgehog (Hh) signaling pathway is known 
to play essential roles in multiple aspects of embry-
onic development. Dysregulation in Hh signaling has 
been  implicated  in  the  pathogenesis  of  a  variety  of 
human tumors including tumors of skin, cerebellum, 
muscle,  lung,  digestive  tract,  pancreas  and  pros-
tate [4-9]. Furthermore, the activation of the Hh sig-
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naling pathway is associated with the malignancy of 
tumors  and  their  progression  to  metastatic  stag-
es [10,11].  Glioma-associated  oncogene  homolog 
1(Gli-1)  protein  is  a  component  in  Hh  signaling 
pathway,  which  functions  as  an  activator  of  tran-
scription [12,  13].  Cyclin D2  and FOXM1  have  been 
identified as the downstream target genes of Gli-1 in 
basal cell carcinomas [14, 15]. Accumulating evidenc-
es have shown that Gli-1 is involved in tumor pro-
gression [16, 17]. 
The aim of the present study is  to explore the 
potential role of Gli-1 in colon cancer development. 
For  this  purpose,  Gli-1  protein  expression  was  de-
tected  in  colon  cancer  and  normal  colon  tissues  by 
immunohistochemistry  using  tissue  microarray.  In 
addition, the correlation of Gli-1 protein expression 
with the clinicopathological data and prognostic var-
iables was analyzed.  
Materials and methods 
Patients and Tissue samples 
Tissue samples were collected from patients with 
colon cancer who underwent surgical operation in the 
Second  Hospital  of  Shandong  University  from  July 
2002  to  December  2007.  Formalin-fixed  and  paraf-
fin-embedded tissue specimens from 96 patients with 
colon cancer were included. All patients received no 
chemotherapy and/or other therapies before surgical 
operation.  Table  1  presents  the  clinicopathological 
data  of  the  96  patients.  All  hematoxylin  and  eosin 
(H&E)-stained slides for each patient were reviewed 
by two pathologists. Clinical and pathological classi-
fication and staging were determined according to the 
American Joint Committee on Cancer criteria [18]. The 
study protocol was approved by the ethics committee 
of  Shandong  University.  Written  informed  consent 
was obtained from each participant before data col-
lection. 
Tissue microarray (TMA) 
For each H&E-stained slide, two representative 
areas were selected and the corresponding spots were 
marked on the surface of the paraffin block. Using a 
tissue microarray punching instrument, the selected 
areas were punched out and were placed into the re-
cipient block side by side. Each tissue core was 2 mm 
in diameter and was assigned with a unique tissue 
microarray location number that was linked to a da-
tabase containing other clinicopathological data. 
Immunohistochemistry (IHC) 
The expression of Gli-1 was detected by strep-
tavidin-peroxidase-biotin  (SP)  immunohistochemical 
method. In brief, paraffin-embedded specimens were 
cut into 4μm sections and baked at 60°C for 60 min. 
The  sections  were  deparaffinized  with  xylenes  and 
rehydrated.  Then  sections  were  submerged  into 
EDTA antigenic retrieval buffer in a pressure cooker 
for 10 minutes and then cooled at room temperature 
for  20  minutes.  The  sections  were  treated  with  3% 
hydrogen  peroxide  in  methanol  to  quench  the  en-
dogenous peroxidase activity, followed by incubation 
with normal serum to block nonspecific binding. The 
sections were incubated with Gli-1 monoclonal anti-
body  (1:50;  Santa  Cruz;  sc-20687,  CA)  overnight  at 
4°C. After washing, the tissue sections were incubated 
with  biotinylated  secondary  antibody  (Maixin  Bio-
technology Company, Fuzhou, China) for 1h at room 
temperature, followed by incubation with streptavi-
din-horseradish  peroxidase  for  20  minutes.  After 
washing  with  PBS,  diaminobenzidine  (DAB)  was 
added  for  visualization.  The  sections  were  counter-
stained with haematoxylin. For negative controls, the 
anti-Gli-1 antibody was replaced with PBS. 
 
Table 1 Clinicopathological parameters in relation to 
nuclear Gli-1 immunoreactivity. 
Variable  Categorization  Patients 
n(%) 
GLi-1 expressiona  P valueb 
high  low 
Gender           
  male  60  44  16   
  female  36  32  4  0.354 
Age           
  ≥60  50  36  14   
  ＜60  46  40  6  0.402 
Tumour 
size 
         
  ≥5cm  42  30  12   
  ＜5cm  54  46  8  0.086 
Tumour 
grade 
(WHO) 
         
  G1+G2  64  48  16   
  G3+G4  32  28  4  0.958 
Lymph 
node 
status 
         
  N+  51  49  2   
  N0  45  27  18  0.022 
T stages           
  T2  30  21  9   
  T3  45  34  11   
  T4  21  19  2  0.030 
aGLi-1 expression, high means IRS≥6 and low means IRS＜6 
bP values were evaluated by chi-square test or the Fisher’s exact test 
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Evaluation of Immunohistochemical Staining 
The  stained  slides  were  reviewed  and  scored 
independently  by  two  observers  blinded  to  the  pa-
tients’  information.  Gli-1  protein  expression  was 
evaluated  using  the  Immuno-Reactive-Score  (IRS) 
system  (combining  positive  cell  ratio  and  staining 
intensity) as suggested by Remmele and Stegner [19]. 
Staining  intensity  was  graded  according  to  the  fol-
lowing criteria: 0 (-, no staining); 1 (+, weak staining= 
light  yellow);  2  (++,  moderate  staining  =  yellow 
brown) and 3 (+++, strong staining = brown). IRS is 
the product of staining intensity and the percentage of 
positively stained cells (graded between 0 and 4, be-
ing 1 = <25%, 2 = 25%–50%; 3 = 51%–75%, and 4 = 
>75%, respectively). Cases with discrepancies in IRS 
score were discussed together with other pathologists 
until consensus was reached. 
Statistical Analysis 
Analyses  were  performed  using  the  statistical 
software package SPSS 13.0 (SPSS, Chicago, IL, USA). 
A  two-sided  Fisher's  exact  test  or  Χ2  test  was  per-
formed to analyze possible associations between Gli-1 
expression  and  clinical  parameters.  The  cumulative 
survival time was computed using the Kaplan-Meier 
method  and  compared  by  the  log-rank  test.  Multi-
variate analyses were based on the Cox proportional 
hazards  regression  model.  P  <  0.05  was  considered 
statistically significant. 
Results 
Gli-1  protein  expression  and  localization  was 
studied on a large TMA including normal (n = 26) and 
tumorous  colon  tissues  (n =  96).  Gli-1  staining  was 
detectable in both the cytoplasm and the nucleus of 
benign and malignant colon epithelial cells. However, 
nuclear expression was more abundant, and as Gli-1 
is a transcription factor, nuclear Gli-1 expression was 
scored for subsequent data analyses and correlation 
studies. In the nucleus of normal colon tissues (Figure 
1A), Gli-1 protein expression was less abundant (me-
dian IRS =4) than in the nucleus of colon cancer cells 
(median IRS = 8) (P = 0.037). In the cells of the colon 
cancer, Gli-1 expression was present in different in-
tensities and different cell distributions. Following the 
staging criteria of stain intensity, no cases were iden-
tified as completely negative, 10 cases (10.4%) were 
identified as “+” (Figure 1B), 22 cases (23.0%) were 
identified as “++” (Figure 1C), and 64 cases (66.7%) 
were identified as “+++” (Figure 1D). We evaluated 
Gli-1 protein expression in colon cancer cells by de-
termining the IRS, with scores of 1, 2, 3, 4, 6, 8, 9 or 12. 
The optimal cutoff value for high and low expression 
level was identified: an IRS score of ≥ 6 was used to 
define tumors with high expression of Gli-1, and an 
IRS score of <6 was used to indicate low expression. 
The high level (IRS≧6), low level (IRS<6) expression 
of  Gli-1  in  colon  cancer  was  observed  in  76  cases 
(79.2%) and 20 cases (20.8%), respectively. 
 
 
Figure  1  Immunohistochemical  expression  analysis  of  GLi-1 
protein in normal colon tissue, and colon tumours using a TMA(SP, 
200×). (A) normal colon tissue, Gli-1 negative. (B) colon cancer 
tissue, Gli-1 positive + , the staining is weak. (C) colon cancer 
tissue, Gli-1 positive ++ , the staining is moderate. (D) Colon 
cancer tissue, Gli-1 positive ++ +, the staining is strong. 
 
 
There was no significant correlation between the 
expression level of Gli-1 and biological factors such as 
patients’ age (P=0.402), gender (P=0.354), tumor size 
(P = 0.086), Tumor grade (P = 0.958). In contrast, sta-
tistical  analyses  indicated  that  Gli-1  expression  was 
positively related to lymph node status, T stages and 
the  correlation  was  statistically  significant  (P= 
0.022/0.030, respectively). The results of these anal-
yses are summarized in Table 1. 
Of the 96 patients with colon cancer, none was 
lost to follow-up. The median observation period was 
38.4 months (ranged, 5.6–60.0 months), with 62 post-
operative live metastases. The median postoperative 
live metastasis-free survival was 30.27±8.99 months. 
To answer the question whether Gli-1 overexpression 
might have an impact on patients' clinical outcome. 
Univariate survival probability curves were calculat-
ed based on the immunohistochemical results. Using 
Kaplan-Meier  analysis  we  found  that  postoperative 
live metastasis-free survival in the group of low Gli-1 
expression was significantly longer than that of high 
expression  (48.22±10.03  vs  20.46±6.32  months, 
P=0.001)  (Figure  2).  Multivariate  analysis  showed 
Gli-1  expression  status  was  evaluated  as  an  inde-
pendent prognostic factor for postoperative live me-
tastasis-free survival (P = 0.002). Int. J. Med. Sci. 2012, 9 
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Figure  2  Colon cancer patients expressing high GLi-1 protein 
(IRS≥6)  show  unfavourable  prognosis.  Univariate  Kaplan-Meier 
analysis was performed on the basis of GLi-1 expression results 
derived from the TMA. Patients with low GLi-1 expression(IRS＜
6) displayed longer liver metastasis-free survival estimation (upper 
graph) compared to patients with high nuclear GLi-1 expression 
(lower graph) (P =0.001). 
 
Discussion 
Gli-1,  which  is  located  on  chromosome 
12q13.2-q13.3, was initially identified as an amplified 
gene in a human malignant glioma [12]. Gli-1 and the 
other two members of the Gli family, namely, Gli-2 
and Gli3, are the nuclear mediators of the Shh signal-
ing pathway that plays an essential role in the regula-
tion of early development of central nervous system 
[20]. For example, the Shh-Gli-1 pathway is required 
for  the  differentiation  of  the  floor  cell  and  ventral 
neurons  in  the  neural  tube,  granule  cell  precursor 
proliferation  in  the  cerebellum,  and  dorsal  brain 
growth  [21-23].  Besides  its  role  in  normal  develop-
ment, Shh-Gli-1 pathway has been implicated in tu-
morigenesis,  [20,  24-26].  There  has  been  evidence 
showing that dysregulation of Shh-Gli-1 pathway is 
associated  with  the  development  of  oesophageal 
squamous cell carcinomas, basal cell carcinomas and 
brain tumors [17,27,28].  
In the present study, we examined the Gli-1 ex-
pression in paraffin-embedded tumor samples using 
the IHC method with the monoclonal antibody. Our 
results showed that Gli-1 is in the cytoplasm and nu-
cleus  of  cells  as  the  product  leaflet  of  the  antibody 
indicates.  Previous  studies  by  Yoshikawa  et  al  [29] 
and Mori et al [17] have demonstrated that nuclear 
staining pattern of Gli-1 in cancer cells is associated 
with early recurrence and poor prognosis. Therefore, 
in the present study, the evaluation of Gli-1 expres-
sion by the Immuno-Reactive-Score (IRS) system was 
based on the nuclear staining. 
Abberant Gli-1 expression has been implicated in 
a variety of solid tumors. ten Haaf A et al [30] studied 
Gli-1 expression in paraffin-embedded breast cancer 
samples and showed that increased Gli-1 expression 
is correlated with unfavorable overall survival, higher 
tumour  stage  and  an  increased  number  of  tu-
mour-positive axillar lymph node. Similarly, Zhu W 
et al [31] reported that Gli-1 expression is correlated 
with large tumor size, locoregional progression and 
poor  locoregional  progression-free  survival,  distant 
progression-free  survival  and  overall  survival  in 
esophageal  squamous  cell  carcinomas.  In  patients 
with head and neck squamous cell carcinoma, high 
Gli-1 expression was also found to be associated with 
poorer outcomes and higher TNM stages [32]. 
In  the  present  study,  high  Gli-1  expression 
(IRS≥6)  in  the  colon  cancer  tissues  was  detected  in 
76%  of  the  patients.  Furthermore,  Gli-1  expression 
level is correlated with lymph node metastasis (P = 
0.042) and T status (P = 0.030), which suggests that 
Gli-1 may have some correlation with worse biologi-
cal behavior and clinical aggressiveness. Our findings 
are consistent with the results of a previous study by 
Xu M et al [33].  
The molecular mechanism underlying liver me-
tastasis in colon cancer is  unclear. Traditional clini-
copathological parameters including the depth of in-
vasion, the presence of venous invasion, and lymph 
node metastasis, have limited prognostic values [34]. 
Other variables, such as CD10, CD44, VEGF, TGF-a 
and the density of macrophages in the invasive front 
have been shown to be correlated with liver metasta-
sis,  however  the  predictive  efficacy  of  these  factors 
remains uncertain [35]. In the present study, postop-
erative  live  metastasis-free  survival  in  the  group  of 
low  Gli-1  expression  was  significantly  longer  than 
that of high expression (P=0.001). Furthermore, result 
of multivariate analysis demonstrated that  Gli-1 ex-
pression  was  an  independent  prognostic  factor  for 
postoperative  live  metastasis-free  survival.  To  our 
knowledge, this is the first report of the relationship 
between Hh signaling pathway and postoperative live 
metastasis. These findings suggested that the abberant 
expression of Gli-1 might contribute to the develop-
ment of colon cancer and postoperative liver metas-
tasis. 
Conclusion 
In the present study, we demonstrated Gli-1 ex-
pression  is  upregulated  in  colon  cancer  cells.  Fur-
thermore, the Gli-1 level in colon cancer cells is cor-Int. J. Med. Sci. 2012, 9 
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related with lymph node metastasis, T stage, postop-
erative liver metastasis-free survival. These findings 
suggested abberant Gli-1 expression may play a role 
in  the  pathogenesis  of  colon  cancer,  and  raised  the 
possibility of using Gli-1 as a prognostic marker for 
poor  liver  metastasis-free  survival  in  patients  with 
colon cancer.  
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